You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 3, March 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Nail Diseases
 •Psoriasis
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Antonella Tosti, MD; Carlos Ricotti, MD; Paolo Romanelli, MD; Norma Cameli, MD; Bianca Maria Piraccini, MD

Arch Dermatol. 2009;145(3):269-271.

Objective  To evaluate the therapeutic efficacy of acitretin in patients with isolated nail psoriasis.

Design  Open study involving 36 patients with moderate to severe nail psoriasis treated with acitretin.

Setting  University-based outpatient dermatology clinic specializing in nail diseases.

Patients  A total of 27 men and 9 women (mean age, 41 years) with nail psoriasis.

Intervention  Therapy consisted of acitretin, 0.2 to 0.3 mg/kg/d, for 6 months.

Main Outcome Measures  Clinical evaluation, and Nail Psoriasis Severity Index (NAPSI) and modified NAPSI scores before therapy, every 2 months during therapy, and 6 months after treatment.

Results  The mean percentage of reduction of the NAPSI score after treatment was 41%; the mean percentage of reduction of the modified NAPSI score of the target nail was 50%. Clinical evaluation at 6 months showed complete or almost complete clearing of the nail lesions in 9 patients (25%), moderate improvement in 9 (25%), mild improvement in 12 (33%), and no improvement in 6 (11%).

Conclusion  Results from low-dose acitretin therapy show NAPSI score reductions comparable with those studies evaluating biologic drugs for nail psoriasis and suggest that low-dose systemic acitretin should be considered in the treatment of nail psoriasis.


Author Affiliations: Departments of Dermatology, University of Bologna, Bologna Italy (Drs Tosti and Piraccini), Miller School of Medicine, University of Miami, Miami, Florida (Drs Ricotti and Romanelli), and Istituto Fisioterapici Ospitalieri, Rome, Italy (Dr Cameli).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Dermatology
Arch Dermatol. 2009;145(3):239.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.